Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting · Phase 1 · NCT06223516
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- AbbVie
- Tested
- Subcutaneous (SC) Etentamig (drug), Intravenous (IV) Etentamig (drug)
- Dates
- Started 2024-06-17; completion 2027-12
- Results posted
- Not yet
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of Etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABB…
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.2M in research payments for this study in 2025 (49 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Saurabh Chhabra, M.D. Hematology & Oncology · Scottsdale, AZ
- Dickran G. Kazandjian, M.D. Hematology & Oncology · Miami, FL
- Vivek Roy, MD Hematology & Oncology · Jacksonville, FL
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Prashant Kapoor, MD Hematology · Rochester, MN
- John T. Mckay, D.O. Hematology & Oncology · Winston Salem, NC
- Meera Mohan, M.D Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Hospital, AZ $454,340
- Wake Forest University $261,821
- Mayo Clinic Rochester $233,715
- Mayo Clinic $161,819
- Medical College of Wisconsin $51,175
- University of Michigan Health System, MI $47,939
- University of Miami $8,665
- Mayo Clinic Jacksonville $5,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.